Myelodysplastic Syndromes Clinical Trials

74 studies are recruiting for myelodysplastic syndromes in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

   Background: Myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) are blood disorders that can cause serious complications in children and adults. MDS and MDS/MPN can also progress to acute myeloid leukemia. Treatments for these disorders are risky and not always …

   Stage

   Phase 1

   Ages

   12 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06303193 on ClinicalTrials.gov

2. Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

   This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with myelofibrosis or myelodysplastic syndrome and anemia.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Banner MD Anderson, Gilbert, Arizona

   Locations

   32 in total

   Run by

   Disc Medicine, Inc

   See if you can join NCT05320198 on ClinicalTrials.gov

3. Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

   The purpose of this study is to see if see if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland, Ohio

   Run by

   Case Comprehensive Cancer Center

   See if you can join NCT06904482 on ClinicalTrials.gov

4. A Study of BGB-11417 in Participants With Myeloid Malignancies

   The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Tampa General Hospital, Tampa, Florida

   Locations

   47 in total

   Run by

   BeOne Medicines

   See if you can join NCT04771130 on ClinicalTrials.gov

5. A Telehealth Advance Care Planning Intervention

   The objective of this project is to conduct a pilot randomized trial to assess the preliminary efficacy of a telehealth-delivered Serious Illness Care Program on healthcare communication, patient anxiety and distress, as well as completion of advance directives (specifically MOLST and healthcare pr…

   Stage

   Not phased

   Ages

   60 and older

   Site

   University of Rochester, Rochester, New York

   Run by

   University of Rochester

   See if you can join NCT05875805 on ClinicalTrials.gov

6. A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

   To learn if olutasidenib can help to control CCUS, MDS, and/or CMML. The safety of the drug will also be studied.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Miami, Miami, Florida

   Locations

   2 in total

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06566742 on ClinicalTrials.gov

7. A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

   The main aim of this study is to learn how safe elritercept is and how well adults with anemia associated with lower-risk MDS tolerate treatment with different doses of elritercept. Other aims are to learn how safe elritercept is by looking at how many participants have MDS that worsens during the …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Genesis Cancer and Blood Institute, Hot Springs, Arkansas

   Locations

   53 in total

   Run by

   Takeda

   See if you can join NCT04419649 on ClinicalTrials.gov

8. A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

   The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also chec…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   177 in total

   Run by

   Takeda

   See if you can join NCT06499285 on ClinicalTrials.gov

9. TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

   The purpose of this study is to test the feasibility and safety of early cessation of tacrolimus following allogeneic hematopoietic cell transplantation (HCT). Post-HCT tacrolimus is given to prevent graft-vs-host-disease (GVHD), but with the use of post-transplant cyclophosphamide (PTCy), the mode…

   Stage

   Phase 1

   Ages

   18 to 80

   Site

   Stanford University, Palo Alto, California

   Run by

   Stanford University

   See if you can join NCT07302776 on ClinicalTrials.gov

10. eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation

    The goal of this study is to test an electronic health (eHealth) mindfulness-based music therapy intervention to improve health-related quality of life and reduce symptom burden and disease activity in patients undergoing stem cell transplantation.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Miami, Miami, Florida

    Run by

    University of Miami

    See if you can join NCT07469592 on ClinicalTrials.gov

11. Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

    This phase 2 study aims to confirm the efficacy observed in the prior phase 1 trial in Cohort 1 and to evaluate the safety of IFN-γ in combination with DLI in Cohort 2, the haploidentical donor alloSCT recipient cohort. The study will further contribute to this effort through the collection of leuk…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Washington University, St Louis, Missouri

    Locations

    3 in total

    Run by

    Sawa Ito, MD

    See if you can join NCT06529731 on ClinicalTrials.gov

12. Mosaic Trial for Stem Cell Transplant Recipients

    The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recru…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Georgetown University School of Medicine, Washington D.C., District of Columbia

    Locations

    3 in total

    Run by

    Northwestern University

    See if you can join NCT06960993 on ClinicalTrials.gov

13. Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS

    Background: Myelodysplastic syndromes (MDS) occur when the cells that make blood cells are abnormal. There are limited treatment options for MDS. Researchers want to learn more through this natural history study so they can develop better treatments. Objective: To study the natural course of MDS an…

    Stage

    Not phased

    Ages

    0 to 120

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT05350748 on ClinicalTrials.gov

14. Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)

    Patients with clonal cytopenia of undetermined significance (CCUS) and lower-risk myelodysplastic syndromes (MDS) have a life expectancy of 5 to 10 years. Mortality in these patients results from progression of disease to higher-risk MDS or acute myeloid leukemia (AML) and cardiovascular events. Cu…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT05483010 on ClinicalTrials.gov

15. Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies

    Background: Myelodysplastic syndromes (MDS) are disorders of blood stem cells that can develop into blood cancers. Treatment options are limited. To find better treatments, researchers need to better understand how MDS develops. To do that, they must be able to compare biospecimens from people with…

    Stage

    Not phased

    Ages

    18 to 120

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT05588154 on ClinicalTrials.gov

16. Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens

    This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and…

    Stage

    Not phased

    Ages

    Up to 30

    Site

    Connecticut Children's Medical Center, Hartford, Connecticut

    Locations

    8 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04968834 on ClinicalTrials.gov

17. HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

    This is a Phase I dose finding study of GTB-3650 (anti-CD16/IL-15/anti-CD33) Tri-Specific Killer Engager (TriKE®) for the treatment of select CD33-expressing refractory/relapsed myeloid malignancies in adults ≥ 18 years of age who are not a candidate for potentially curative therapy, including hema…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Masonic Cancer Center, Minneapolis, Minnesota

    Run by

    Masonic Cancer Center, University of Minnesota

    See if you can join NCT06594445 on ClinicalTrials.gov

18. CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

    The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is effective in preventing GVHD, but immune reconst…

    Stage

    Not phased

    Ages

    Up to 25

    Site

    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

    Run by

    Children's Hospital of Philadelphia

    See if you can join NCT03810196 on ClinicalTrials.gov

19. Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

    This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies. Orca-T is an allogeneic stem cell and T-cell immunotherapy biologic manuf…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UCLA Department of Medicine, Los Angeles, California

    Locations

    6 in total

    Run by

    Orca Biosystems, Inc.

    See if you can join NCT07216443 on ClinicalTrials.gov

20. Allo HSCT Using RIC and PTCy for Hematological Diseases

    This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamid…

    Stage

    Phase 2

    Ages

    Up to 75

    Site

    Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

    Run by

    Masonic Cancer Center, University of Minnesota

    See if you can join NCT05805605 on ClinicalTrials.gov

21. Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants

    Background: Hereditary hematopoietic malignancy (HHM) syndromes are a group of inherited disorders that raises the risk of blood cancers. Many people with HHMs have changes in a gene (DDX41) that makes it more likely that they will develop myelodysplastic syndrome (MDS), acute myeloid leukemia (AML…

    Stage

    Not phased

    Ages

    0 to 120

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT07019155 on ClinicalTrials.gov

22. A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

    This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.

    Stage

    Phase 1

    Ages

    12 to 78

    Site

    City of Hope, Duarte, California

    Locations

    12 in total

    Run by

    Orca Biosystems, Inc.

    See if you can join NCT03802695 on ClinicalTrials.gov

23. Registry of Older Patients With Cancer

    RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.

    Stage

    Not phased

    Ages

    65 and older

    Site

    Seby B. Jones Cancer Center, Boone, North Carolina

    Locations

    7 in total

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT01137825 on ClinicalTrials.gov

24. Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

    The study is a Phase II clinical trial. Patients will receive intensity-modulated total marrow irradiation (TMI) at a dose of 9 Gray (Gy) with standard myeloablative fludarabine intravenous (IV) and targeted busulfan (FluBu4) conditioning prior to allogeneic hematopoietic stem cell transplant (HSCT…

    Stage

    Phase 2

    Ages

    18 to 65

    Site

    University of Illinois Cancer Center, Chicago, Illinois

    Run by

    University of Illinois at Chicago

    See if you can join NCT06802315 on ClinicalTrials.gov

25. Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

    The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.

    Stage

    Phase 1

    Ages

    18 to 70

    Site

    Stanford University, Palo Alto, California

    Run by

    Stanford University

    See if you can join NCT06551584 on ClinicalTrials.gov